HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV15) SEROTYPES IN ADULTS 65 YEARS AND OLDER IN THE U.S.
Abstract
Background
This analysis quantifies the epidemiologic and economic burden of pneumococcal disease attributable to 15-valent pneumococcal conjugate vaccine (PCV15) serotypes in a hypothetical cohort of US adults aged 65 years and older in the US.
Methods
A Markov model was used to estimate pneumococcal disease cases, deaths and costs attributable to PCV15 serotypes. A cohort of unvaccinated adults aged ≥65 years from 2017 were tracked until death. Economic burden was estimated from a payer perspective, by multiplying the number of inpatient/outpatient visits by the cost per inpatient/outpatient visits. Costs were discounted at 3% per year.
Results
An estimated 74,956 cases of IPD; 10,336 cases of IPD related deaths; 2,286,581 cases of NBPP hospitalizations and 135,566 cases of NBPP related deaths were attributable to PCV15 serotypes in adults aged ≥65 years in the U.S. Total lifetime discounted healthcare costs attributable to PCV15 serotypes were estimated to be approximately $19.9 million. 36.3% of these cases, deaths and costs were attributable to serotypes 22F and 33F and 42.4% were attributable to serotype 3.
Conclusions
PCV15 serotypes contribute to substantial health and economic burden of pneumococcal disease among older adults (aged ≥65 years) in the U.S., majority of which is attributable to the serotypes 3, 22F, and 33F.